Yuhan Yanghang Signs Agreement with Pluto for Sales of Pet Joint Medical Devices

Yuhan Corporation announced on the 11th that it signed a business agreement with Pluto, a pharmaceutical development specialist company, on the 6th for the sale of 'Aniconju,' a veterinary medical device for pet joint health.

Yuhan Corporation Anicon Injection. [Photo by Yuhan Corporation]

Through this agreement, Yuhan Corporation plans to launch Aniconju in the domestic market around mid-September and further strengthen its pet business capabilities in cooperation with Pluto.

Aniconju is a veterinary medical device composed of polynucleotide (PN) ingredients and is an injectable product that can be used for pets with osteoarthritis. It received official approval from the Animal and Plant Quarantine Agency in April.

The main ingredient, PN, is DNA extracted from salmon testes and is optimized as a regenerative active substance. The PN component maintains high elasticity within the joint cavity and reduces mechanical friction in the joint through physical repair of the tissue.

Kim Seong-su, Executive Director of Yuhan Corporation, said, "As pets age, various diseases such as joint disorders occur, and we expect that the launch of Aniconju will greatly help improve the quality of life for pets suffering from osteoarthritis." He added, "Unlike existing surgical operations, painkillers, and nutritional supplements, Aniconju shows quick effects through a simple procedure without anesthesia, which will expand treatment opportunities and increase treatment satisfaction for veterinary hospitals and pet owners."

Meanwhile, Yuhan Corporation is applying for not only domestic patents but also international patent applications (PCT) for Aniconju. Yuhan Corporation is entering the pet market with products such as 'Zedacure,' a cognitive function enhancer for dogs, soft food 'Willopet,' and customized food 'RecipeV.'

This content was produced with the assistance of AI translation services.